Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Long-term safety of abobotulinumtoxinA for the treatment of glabellar lines: results from a 36-month, multicenter, open-label extension study.

Schlessinger J, Dover JS, Joseph J, Monheit G, Nelson DB, Albright CD, Axford-Gatley RA, Cohen JL; Dysport Study Group.

Dermatol Surg. 2014 Feb;40(2):176-83. doi: 10.1111/dsu.12404. Epub 2013 Dec 26.

PMID:
24372978
2.

Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines.

Moy R, Maas C, Monheit G, Huber MB; Reloxin Investigational Group.

Arch Facial Plast Surg. 2009 Mar-Apr;11(2):77-83. doi: 10.1001/archfacial.2009.5.

PMID:
19289677
3.

An analysis of efficacy data from four phase III studies of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.

Baumann L, Brandt FS, Kane MA, Donofrio LM.

Aesthet Surg J. 2009 Nov;29(6 Suppl):S57-65. doi: 10.1016/j.asj.2009.09.012.

PMID:
19945006
4.

An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.

Rubin M, Dover J, Maas C, Nestor M.

Aesthet Surg J. 2009 Nov;29(6 Suppl):S50-6. doi: 10.1016/j.asj.2009.09.010.

PMID:
19945005
5.

An analysis of the long-term safety data of repeat administrations of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.

Cohen JL, Schlessinger J, Cox SE, Lin X; Reloxin Investigational Group.

Aesthet Surg J. 2009 Nov;29(6 Suppl):S43-9. doi: 10.1016/j.asj.2009.09.003.

PMID:
19945004
6.

The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment.

Rubin MG, Dover J, Glogau RG, Goldberg DJ, Goldman MP, Schlessinger J.

J Drugs Dermatol. 2009 May;8(5):439-44.

PMID:
19537366
7.

Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.

Carruthers A, Carruthers J, Coleman WP 3rd, Donofrio L, Flynn T, Gold M, Heinz M, Harrington L, Jones D, McDaniel D, Rohrer T, Schlöbe A, Solish N, Weiss RA.

Dermatol Surg. 2013 Apr;39(4):551-8. doi: 10.1111/dsu.12100. Epub 2013 Feb 4.

PMID:
23379292
8.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Repeated OnabotulinumtoxinA Treatments in Subjects With Crow's Feet Lines and Glabellar Lines.

Carruthers J, Rivkin A, Donofrio L, Bertucci V, Somogyi C, Lei X, Davis PG, Campo A, Beddingfield FC.

Dermatol Surg. 2015 Jun;41(6):702-11. doi: 10.1097/DSS.0000000000000357.

PMID:
25993609
9.

Remodeling of periorbital, temporal, glabellar, and crow's feet areas with hyaluronic acid and botulinum toxin.

Beer KR, Julius H, Dunn M, Wilson F.

J Cosmet Dermatol. 2014 Jun;13(2):143-50. doi: 10.1111/jocd.12082.

PMID:
24910278
10.

An internally controlled, double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA.

Nettar KD, Yu KC, Bapna S, Boscardin J, Maas CS.

Arch Facial Plast Surg. 2011 Nov-Dec;13(6):380-6. doi: 10.1001/archfacial.2011.37. Epub 2011 Jun 20. Erratum in: Arch Facial Plast Surg. 2012 Mar;14(2):140.

PMID:
21690460
11.

Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.

Carruthers A, Carruthers J, Said S.

Dermatol Surg. 2005 Apr;31(4):414-22; discussion 422.

PMID:
15871316
12.
13.

Phase IV study comparing incobotulinumtoxinA and onabotulinumtoxinA using a 1:1.5 dose-conversion ratio for the treatment of glabellar frown lines.

Prager W, Rappl T.

J Cosmet Dermatol. 2012 Dec;11(4):267-71. doi: 10.1111/jocd.12001. Epub 2012 Oct 2.

PMID:
23174049
14.

Safety of botulinum toxin A in aesthetic treatments: a systematic review of clinical studies.

Cavallini M, Cirillo P, Fundarò SP, Quartucci S, Sciuto C, Sito G, Tonini D, Trocchi G, Signorini M.

Dermatol Surg. 2014 May;40(5):525-36. doi: 10.1111/dsu.12463. Epub 2014 Feb 28. Review.

PMID:
24575858
16.

Botulinum toxin A (Botox Cosmetic): a review of its use in the treatment of glabellar frown lines.

Frampton JE, Easthope SE.

Am J Clin Dermatol. 2003;4(10):709-25. Review.

PMID:
14507232
17.
18.
19.

AbobotulinumtoxinA for reduction of glabellar lines in patients with skin of color: post hoc analysis of pooled clinical trial data.

Taylor SC, Callender VD, Albright CD, Coleman J, Axford-Gatley RA, Lin X.

Dermatol Surg. 2012 Nov;38(11):1804-11. doi: 10.1111/j.1524-4725.2012.02551.x. Epub 2012 Aug 28.

PMID:
22928999
20.

Long-term safety of repeated administrations of a new formulation of botulinum toxin type A in the treatment of glabellar lines: interim analysis from an open-label extension study.

Monheit GD, Cohen JL; Reloxin Investigational Group.

J Am Acad Dermatol. 2009 Sep;61(3):421-5. doi: 10.1016/j.jaad.2009.03.049. Epub 2009 Jul 3.

PMID:
19577326

Supplemental Content

Support Center